18889881171
Kalkine 0
countryflagUS

Allergy Therapeutics plc

Healthcare US AGYTF

0.085USD
-(-%)

Last update at 2025-05-16T13:30:00Z

Day Range

0.090.09
LowHigh

52 Week Range

0.010.06
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap377.04M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.01600M
  • Revenue TTM55.20M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 34.61M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -49.82900M -12.65700M 3.66M 8.07M 4.29M
Minority interest - - - - 0.00000M
Net income -51.02600M -13.77600M 2.89M 7.06M 3.47M
Selling general administrative 25.09M 20.83M 20.67M 19.63M 17.59M
Selling and marketing expenses 23.70M 26.00M 25.20M 24.85M 27.00M
Gross profit 34.61M 49.51M 62.23M 58.00M 55.34M
Reconciled depreciation 4.23M 4.17M 4.13M 3.91M 2.09M
Ebit -33.11900M -11.98800M 4.15M 8.57M 4.49M
Ebitda -28.89300M -7.82200M 8.28M 12.49M 6.58M
Depreciation and amortization 4.23M 4.17M 4.13M 3.91M 2.09M
Non operating income net other - - - - 0.00000M
Operating income -36.12900M -12.24500M 4.03M 8.31M 4.39M
Other operating expenses 94.40M 85.01M 80.30M 69.89M 69.33M
Interest expense 2.75M 0.67M 0.49M 0.50M 0.20M
Tax provision 1.20M 1.12M 0.77M 1.01M 0.83M
Interest income 0.33M 0.26M 0.12M 0.27M 0.10M
Net interest income -2.42000M -0.41200M -0.37400M -0.23800M -0.09800M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 1.20M 1.12M 0.77M 1.01M 0.83M
Total revenue 60.95M 72.77M 84.33M 78.20M 73.72M
Total operating expenses 68.06M 61.75M 58.19M 49.69M 50.95M
Cost of revenue 26.34M 23.26M 22.11M 20.20M 18.38M
Total other income expense net -13.70000M -0.41200M -0.37400M -0.23800M -0.09800M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -51.02600M -13.77600M 2.89M 7.06M 3.47M
Net income applicable to common shares -51.02600M -13.77600M 2.89M 7.06M 3.47M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 64.83M 68.40M 73.58M 88.09M 86.22M
Intangible assets 1.37M 1.05M 1.69M 1.41M 1.27M
Earning assets - - - - -
Other current assets 8.02M - - 0.53M -
Total liab 61.12M 73.18M 35.18M 39.55M 42.44M
Total stockholder equity 3.71M -4.78300M 38.40M 48.53M 43.78M
Deferred long term liab - - - - -
Other current liab 9.68M 0.08M 0.12M 0.03M 0.81M
Common stock 4.77M 0.69M 0.64M 0.64M 0.64M
Capital stock - 0.69M 0.64M 0.64M 0.64M
Retained earnings -198.92700M -168.71900M -117.91000M -107.39800M -112.96100M
Other liab - 19.53M 8.87M 11.91M 14.30M
Good will 3.32M 3.35M 3.35M 3.34M 3.47M
Other assets - 5.81M 5.96M 5.76M 5.90M
Cash 12.71M 14.85M 20.52M 40.27M 36.96M
Cash and equivalents - - - - -
Total current liabilities 20.55M 19.06M 17.80M 18.23M 18.23M
Current deferred revenue - - - - -
Net debt 18.27M 21.55M -9.98600M -29.10100M -24.78300M
Short term debt 2.12M 1.80M 2.02M 1.75M 2.26M
Short long term debt - 0.65M 0.95M 0.96M 0.83M
Short long term debt total 30.99M 36.40M 10.53M 11.17M 12.18M
Other stockholder equity 197.87M 163.25M 155.66M 155.29M 156.11M
Property plant equipment - 23.98M 20.19M 19.72M 20.42M
Total current assets 33.48M 34.21M 42.39M 57.86M 55.17M
Long term investments - - - - -
Net tangible assets - -9.18300M 33.36M 43.78M 39.05M
Short term investments - - - - -
Net receivables - 2.37M 5.91M 4.62M 5.65M
Long term debt - 26.85M 1.50M 2.45M 2.93M
Inventory 12.74M 11.59M 11.41M 10.84M 10.13M
Accounts payable 4.01M 17.17M 15.67M 16.48M 15.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.91M 5.81M 5.96M 5.76M 5.90M
Deferred long term asset charges - - - - -
Non current assets total 31.34M 34.19M 31.19M 30.23M 31.05M
Capital lease obligations - 8.90M 8.08M 7.76M 8.42M
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -5.79200M -3.19800M -2.63900M -2.50900M -3.35300M
Change to liabilities 1.70M -1.87200M 0.55M -2.39900M 0.16M
Total cashflows from investing activities -5.79200M -3.19800M -2.63900M -2.50900M -3.35300M
Net borrowings 24.45M -2.26800M -1.73700M -0.11100M -0.65100M
Total cash from financing activities 28.90M -2.63800M -2.03400M -0.11000M 9.54M
Change to operating activities - - - - 0.00000M
Net income -49.82900M -12.65700M 3.66M 8.07M 4.29M
Change in cash -5.67000M -19.75800M 3.31M 9.52M 11.91M
Begin period cash flow 20.52M 40.27M 36.96M 27.44M 15.53M
End period cash flow 14.85M 20.52M 40.27M 36.96M 27.44M
Total cash from operating activities -28.74500M -14.37200M 8.40M 12.01M 5.60M
Issuance of capital stock 6.49M 0.00300M 0.00400M 0.00100M 10.60M
Depreciation 4.23M 4.17M 4.13M 3.91M 2.09M
Other cashflows from investing activities -0.07700M 0.08M -0.07700M 0.04M -0.25400M
Dividends paid - - - - 0.00000M
Change to inventory -0.14200M -0.58600M -1.11700M -0.70600M -0.54300M
Change to account receivables 3.11M -3.88500M 2.14M 3.69M -1.86400M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 33.37M -1.68400M -1.28100M 0.54M -0.40400M
Change to netincome 13.39M 1.58M -0.19100M 0.92M 2.29M
Capital expenditures 5.71M 3.28M 2.56M 2.55M 3.10M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 4.66M -6.34300M 1.57M 0.59M -2.24500M
Stock based compensation 0.11M 0.47M 0.64M 0.79M 1.37M
Other non cash items 12.08M -0.00700M -1.59700M -1.35800M 0.10M
Free cash flow -34.46000M -17.64800M 5.84M 9.46M 2.50M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGYTF
Allergy Therapeutics plc		 - -% 0.09 - - 6.83 52.42 5.75 -4.3373
ZTS
Zoetis Inc		 0.82 0.50% 163.86 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.15 0.58% 25.93 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.05 0.80% 130.20 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.09 0.64% 14.20 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Allergy Therapeutics plc

Dominion Way, Worthing, United Kingdom, BN14 8SA

Key Executives

Name Title Year Born
Mr. Manuel Llobet CEO & Exec. Director 1964
Mr. Martin Hopcroft Interim Chief Financial Officer NA
Ms. Beverly Lees Group Operations Director NA
Dr. Murray Skinner Chief Scientific Officer NA
Mr. Santiago Puig Bus. Devel. Director NA
Ms. Sue Baker Head of HR NA
Simon Piggott Head of Clinical Science NA
Alan Bullimore Head of Communication & Market Devel. NA
Mr. Russell Picket Group Financial Controller NA
Sara Goldsbrough Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.